Rosellini William Form 4/A NEXEON MEDSYSTEMS / William Rosellini ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Rosellini William

(Last) (First) (Middle)

1708 JAGGIE FOX WAY

(Street)

LEXINGTON KY 40511

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEXEON MEDSYSTEMS INC [ NONE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2016

4. If Amendment, Date of Original Filed (Month/Day/Year)
01/09/2017

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2016		J(2)		158,500(2)	D	$1	12,582,807	I	Shares owned by Rosellini Scientific LLC(1)
Common Stock	09/15/2016		J(3)		39,000(3)	D	$0.5	12,543,807	I	Shares owned by Rosellini Scientific LLC(1)
Common Stock	12/15/2016		J(4)		3,050,000(4)	A	(4)	3,050,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Rosellini Scientific LLC ("RS") is wholly-owned by William Rosellini. Mr. Rosellini has the power to vote and dispose of shares held by RS.

2. Rosellini Scientific transferred 158,500 shares of the Company's common stock upon conversion of a $150,000 loan pursuant to a Debt Conversion Agreement dated September 15, 2016.

3. Rosellini Scientific transferred 39,000 shares of the Company's common stock upon conversion of a $19,470 debt pursuant to a Conversion Agreement dated September 15, 2016.

4. Pursuant to the terms of a License Agreement, Mr. Rosellini sold, assigned and transferred any and all of his right, title and interest in and to the License owned by him related to the certain patents to the Company pursuant to the Patent License Asset Purchase Agreement (the "Purchase Agreement") filed as Exhibit 10.1 to the Company's Form 8-K Current Report filed with the SEC on December 20, 2016. As consideration for the transfer of the patents and the License related thereto, the Company paid to Mr. Rosellini the sum $140,000 in cash and authorized the issuance of 3,050,000 shares of the Company's restricted Common Stock. These shares shall be restricted from transfer by Mr. Rosellini for a period of six months, as required by SEC Rule 16(b)-3.

	/s/ William Rosellini	09/26/2017
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.